Antiretroviral therapy: A guide to the most important trials

Schweizerische Medizinische Wochenschrift

Volumn 127, Issue 11, 1997, Pages 436-443

  Rutschmann, O ^a   Hirschel, B ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; RETROVIRUS; REVIEW; VIRUS INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CLINICAL TRIALS; DIDANOSINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PYRIDINES; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRAL LOAD; ZALCITABINE; ZIDOVUDINE;

EID: 0031002766     PISSN: 00367672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Sous-commission «clinique» de la commission fédérale sur les questions liées au Sida. Nouvelles recommandations pour le traitement du sida. Bull OFS 1995; 3-5.
2. Aber V, Aboulker JP, Babiker AG, Bragman K, Breckenridge AM et al.: Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
3. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-1090.
4. Samuels MA: Update in neurology. Ann Intern Med 1996; 125: 570-576.
5. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B et al.: Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995; 9: 159-163.
6. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426-431.
7. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 1996; 276: 146-154.
8. Sous-commission «clinique» de la commission fédérale sur les questions liées au Sida. Directives pour l'utilisation des médicaments antiviraux dans le traitement de l'infection par le VIH. Bull OFS 1996; 29: 5-7.
9. Schockmel GA, Yerly S, Perrin L: Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr 1997, in press.
10. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R et al.: HIV viral load markers in clinical practice. Nature Med 1996; 2: 625-629.
11. Fischl MA, Richman DD, Grieco MH: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind placebo-controlled study. N Engl J Med 1987; 317: 185-191.
12. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y et al.: Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989; 262: 2405-2410.
13. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA et al.: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 192-197.
14. Concorde Coordinating Committee. Concorde: MRC/ ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-881.
15. Ioannidis JP, Cappelleri JC, Lau J, Skolnik PR, Melville B et al.: Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness (see comments). Ann Intern Med 1995; 122: 856-866.
16. Kinloch-de Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B et al.: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408-413.
17. Perrin L, Yerly S, Lazzarin A, Tambussi G, Hermans P et al.: Reduced viremia and increased CD4/CD8 ratio in patients with primary HIV infection treated with AZT-ddI [Abstract]. 12th Conference on Aids, Vancouver, 1996.
18. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1099-1106.
19. + cells per cubic millimeter. N Engl J Med 1995; 333: 1662-1669.
20. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276: 118-125.
21. Staszewski S, Loveday C, Picazo JJ, Dellamonica P, Skinhoj P et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996; 276: 111-117.
22. Katlama C: Clinical and survival benefit of 3TC in combination with zidovudine-containing regimens in HIV-1 infection: interim results of the CAESAR study [Abstract]. AIDS 1996; 10 (Suppl. 2): S9.
23. Murray HW, Squires KE, Weiss W, Sledz S, Sacks HS et al.: Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J Infect Dis 1995; 171 (Suppl. 2): S123-S130.
24. Gottlieb M, Peterson D, Adler M: Comparison of safety and efficacy of two doses of stavudine (ZERIT, d4T) in a large simple trial in the US parallel track program [Abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995.
25. 3 after at least 6 months ZDV treatment [Abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995.
26. Pollard R, Peterson D, Hardy D, Pedneault L, Rutkiewicz V et al.: Stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects: antiviral effect and safety in an on-going pilot randomized double-blinded trial [Abstract]. 12th Conference on Aids, Vancouver, 1996.
27. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza P et al.: ddI + d4T ± hydroxyurea in moderatly immunosuppressed HIV-1 infected patients [Abstract]. 4th Conference on Retroviruses and Opportunistic Infections, Washington, January 1997.
28. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-955.
29. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996; 334: 1011-1017.
30. Saigo MP, Beattie D, Bragman K, Donatacci L, Jones M et al.: Saquinavir (invirase, SQV) vs. HIVID (zalcitabine, ddC) vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine, ZDV) [Abstract]. 12th Conference on Aids, Vancouver, 1996.
31. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A et al.: Prolongation of life and prevention of Aids complications in advanced HIV immunodeficiency with ritonavir: update [Abstract]. 12th Conference on Aids, Vancouver, 1996.
32. Cameron W, Sun E, Markowitz M, Farthing C, McMahon D et al.: Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [Abstract]. 12th Conference on Aids, Vancouver, 1996.
33. Hirschel B, Lorenzi P, Yerly S, Rutschmann O, Fahti M et al.: Escape of viremia and rapid development of protease mutations in advanced HIV infection treated with saquinavir plus ritonavir [Abstract]. 4th Conference on Retroviruses and Opportunistic Infections, Washington, January 1997.
34. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL et al.: A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996; 10: 485-492.
35. Gulick RM, Mellors J, Havlir D, Eron J, Gonzales C et al.: Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC) [Abstract]. 12th Conference on Aids, Vancouver, 1996.
36. Merluzzi VJ, Hargrave KD, Labadia M: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250: 1411-1413.
37. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 1019-1030.
38. Conway B, Montaner JSG, Cooper D, Vella S, Reiss P et al.: Randomized, double-blind one year study of the immunologic and virologic effects of nevirapine, didanosine and zidovudine combinations among antiretroviral naive, Aids-free patients with CD4 200-600 [Abstract]. AIDS 1996; 10 (Suppl. 2): S15.